REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
- Monday, January 23, 2023, 7:05
- Finance
- Add a comment
– Company has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 – Company also enrolling newly active observational screening study, AFFINITY BEYOND, evaluating AAV8 antibody prevalence in boys with Duchenne – Commercial-scale cGMP material from the REGENXBIO Manufacturing…
About the Author
adminasapcorp has written 41552 stories on this site.